HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC
Cătălin Roșioru
International Association for the Study of Lung Cancer Sep 8 2025 A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC). The results were presented today at the International Association for
din zilele anterioare